Inflammatory reaction following cataract phacoemulsification surgery
Conditions
Interventions
Group A:Loposome Encapsulate Indomethacin Eyedrops after phacoemulsification cataract surgery
Group B:Indomethacin Eyedrops after phacoemulsification cataract surgery
Sponsors
LiBo Pharmaceuticals Science & Technology Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Both male and female subjects with cataract at the age from 18(18 included) to 70; 2. It is clinical definite cataract and indication of phacoemulsification; 3. Subjects have read the subject notice, consented to the treatment and signed a written informed consent form; 4. Subjects would and were able to visit timely in accordance with the requirements.
Exclusion criteria
Exclusion criteria: 1. Systemic inflammation or ocular infection; 2. Combining with glaucoma, uveitis, and traumatic cataract; 3.Pseudo-exfoliation syndrome; 4.Women during pregnancy or lactation; 5. Corneal endothelial cell decompensation; 6. Progressive ocular changes of severe diabetic; 7. Serious heart, lung, liver, kidney dysfunction; 8. Patients suffering from neurological, mental illness, serious endocrine disease or tumor; 9.Patients of systemic autoimmune disease or requiring long-term use of corticosteroids and immunosuppressant; 10. Subjects had accepted local corticosteroids medication two weeks before selected; 11. Subjects had participated in other drug clinical trials four weeks before selected; 12. Subjects that did not fill out the informed consent form and be not able to describes the state of an illness; 13. Subjects with severe complications during phacoemulsification.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of flare;Improvement;cells of Anterior Chambe; | — |
Secondary
| Measure | Time frame |
|---|---|
| scores of symptoms and signs before and after applying eyedrops; | — |
Contacts
Public ContactMingxing Wu
Outcome results
None listed